Back to Screener

Co-Diagnostics, Inc. - Common Stock (CODX)

NASDAQ Nano Cap
$2.63
Market Cap: $9M
Data as of Sep 30, 2025 (TTM)

Investment Snapshot

  • P/B of 0.46 — trading below book value
  • Piotroski F-Score 1/9 — signs of financial weakness
  • Loss-making — negative ROE of -149.5%
  • Revenue declining 84% annually

Co-Diagnostics, Inc. - Common Stock (CODX) is a publicly traded company, listed on the NASDAQ , with a market capitalisation of $9 million . Key value metrics: P/B ratio 0.46, Piotroski F-Score 1 out of 9 .

Value Score

Key Metrics

P/E Ratio
0.46
EPS
$-8.56
Div. Yield
PEG Ratio
P/S Ratio
EV/EBITDA
ROE
ROA
Gross Margin
Op. Margin
Net Margin
Debt/Equity
Current Ratio
Data sourced from SEC EDGAR and Polygon.io. Methodology.

Co-Diagnostics, Inc. - Common Stock — Fundamental Analysis Summary

On financial health, CODX shows a weak Piotroski F-Score of 1/9, a signal of deteriorating financial health, and negative return on equity of -149.5%.

StockPik's composite Value Score for CODX is 57/100 — an above-average value rating. The score is built from ten fundamental signals: P/E, P/B, PEG ratio, P/S ratio, return on equity, gross margin, debt-to-equity, current ratio, dividend yield, and Piotroski F-Score.

CODX reports a high gross margin of 62.3% and a negative operating margin of -3,386.8%.

CODX shows revenue declining at 84% year-over-year, with earnings declining at 25%.

Stocks below book value
Other stocks trading at a discount to net assets (P/B < 1)
How is the Value Score calculated?
Read our full methodology →
What is the Piotroski F-Score?
The 9-point financial health score explained, with worked examples →
Previous
CODI
Next
COEP